PMID- 28682887
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 27
DP  - 2017 Jul
TI  - Atropine 0.5% eyedrops for the treatment of children with low myopia: A 
      randomized controlled trial.
PG  - e7371
LID - 10.1097/MD.0000000000007371 [doi]
LID - e7371
AB  - BACKGROUND: This study aimed to assess the efficacy and safety of atropine 0.5% 
      eyedrops (ATE) for the treatment of children with low myopia (LM). METHODS: In 
      this study, a total of 126 children with LM were randomly divided into an 
      intervention group (administered 0.5% ATE) and a control group (administered a 
      placebo), with 63 children in each group. The outcome measurements were changes 
      in the spherical equivalent (SE), and axial length (AL), as well as adverse 
      events (AEs). RESULTS: Compared with placebo, administration of 0.5% ATE led to 
      less progression in LM, as measured by SE, and less increase in AL (P < .01). In 
      addition, no serious AEs occurred in both the groups. CONCLUSION: About 0.5% ATE 
      was efficacious and safe for controlling myopia in children with LM.
FAU - Wang, Yan-Rong
AU  - Wang YR
AD  - Department of Ophthalmology, The People's Hospital of Yan'an Department of 
      Ophthalmology, Affiliated Hospital of Yan'an University, Yan'an, China.
FAU - Bian, Hong-Li
AU  - Bian HL
FAU - Wang, Qi
AU  - Wang Q
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Ophthalmic Solutions)
RN  - 7C0697DR9I (Atropine)
SB  - IM
MH  - Administration, Ophthalmic
MH  - Atropine/*administration & dosage/adverse effects
MH  - Axial Length, Eye/drug effects
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Myopia/*drug therapy
MH  - Ophthalmic Solutions
MH  - Treatment Outcome
PMC - PMC5502160
COIS- The authors report no conflicts of interest.
EDAT- 2017/07/07 06:00
MHDA- 2017/07/18 06:00
PMCR- 2017/07/07
CRDT- 2017/07/07 06:00
PHST- 2017/07/07 06:00 [entrez]
PHST- 2017/07/07 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
PHST- 2017/07/07 00:00 [pmc-release]
AID - 00005792-201707070-00029 [pii]
AID - MD-D-17-02934 [pii]
AID - 10.1097/MD.0000000000007371 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(27):e7371. doi: 10.1097/MD.0000000000007371.